Overview Financials News + Filings IR Vault Key Docs Charts Ownership Insiders
|
|
OSI PHARMACEUTICALS INC (OSIP)
|
Add to portfolio |
|
|
|
| Price: |
$57.49
| | Metrics |
| OS: |
61.2
|
M
| |
15
|
% ROE
|
| Market cap: |
$3.52
|
B
| |
14
|
% ROIC
|
|
Net cash:
|
$531
|
M
| |
$8.67
|
per share
|
|
EV:
|
$2.99
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
$165
|
M
| |
18.1
|
x EV/EBITDA
|
|
EBIT
|
$154
|
M
| |
19.4
|
x EV/EBIT
|
| EPS |
$1.90
| |
30.2
|
x P/E
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-09 | Dec-31-08 | Dec-31-07 | Dec-31-06 | Dec-31-05 | Dec-31-04 | Sep-30-04 | Sep-30-03 |
| Revenues | 428.1 | 379.4 | 341.0 | 241.0 | 138.4 | 12.3 | 42.8 | 32.4 |
| Revenue growth | 12.9% | 11.2% | 41.5% | 74.1% | 1021.1% | | 32.2% | |
| Cost of goods sold | 8.8 | 9.3 | 9.4 | 8.7 | 5.0 | -1.2 | 9.0 | 0.2 |
| Gross profit | 419.4 | 370.1 | 331.6 | 232.4 | 133.4 | 13.6 | 33.8 | 32.2 |
| Gross margin | 97.9% | 97.5% | 97.2% | 96.4% | 96.4% | 110.1% | 79.0% | 99.5% |
| Selling, general and administrative | 103.0 | 94.9 | 99.2 | 107.5 | 89.2 | 20.3 | 98.9 | 70.5 |
| Research and development | 151.8 | 135.3 | 123.5 | 117.5 | 116.7 | 31.9 | 110.4 | 102.6 |
| EBITA | 164.5 | 139.8 | 108.9 | 7.4 | -72.5 | -46.3 | -175.5 | -141.0 |
| EBITA margin | 38.4% | 36.8% | 31.9% | 3.1% | -52.4% | -374.9% | -410.0% | -435.5% |
| Amortization of intangibles | 0.9 | 2.5 | 1.8 | 1.8 | 15.3 | 3.8 | 18.6 | 9.3 |
| EBIT | 163.6 | 137.3 | 107.1 | 5.6 | -87.8 | -50.1 | -194.1 | -150.3 |
| EBIT margin | 38.2% | 36.2% | 31.4% | 2.3% | -63.4% | -405.7% | -453.5% | -464.2% |
| Pre-tax income | 133.3 | 120.7 | 99.5 | 6.7 | -85.1 | 0.0 | -260.4 | -181.4 |
| Income taxes | 57.3 | -316.0 | 2.7 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 43.0% | | 2.7% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | 75.9 | 441.6 | 60.5 | 6.7 | -157.1 | 0.0 | -260.4 | -181.4 |
| Net margin | 17.7% | 116.4% | 17.7% | 2.8% | -113.5% | 0.0% | -608.3% | -560.3% |
| |
| Diluted EPS | $1.26 | $6.53 | $1.66 | $116.23 | ($1.63) | $0.00 | ($6.50) | ($4.87) |
| Shares outstanding (diluted) | 60.5 | 66.9 | 58.3 | 0.1 | 52.1 | 47.4 | 40.1 | 37.2 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|